173 related articles for article (PubMed ID: 38484377)
1. [Systemic treatment of adult gliomas: a narrative review].
Mangel L
Magy Onkol; 2024 Mar; 68(1):67-75. PubMed ID: 38484377
[TBL] [Abstract][Full Text] [Related]
2. Current and promising treatment strategies in glioma.
Śledzińska P; Bebyn M; Furtak J; Koper A; Koper K
Rev Neurosci; 2023 Jul; 34(5):483-516. PubMed ID: 36062548
[TBL] [Abstract][Full Text] [Related]
3. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive pharmacogenomics characterization of temozolomide response in gliomas.
Tong S; Wang Y; Wu J; Long J; Zhong P; Wang B
Eur J Pharmacol; 2021 Dec; 912():174580. PubMed ID: 34678239
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Rudà R; Pellerino A; Pace A; Carapella CM; Dealis C; Caroli M; Faedi M; Bello L; Migliore E; Marchese G; Bertero L; Cassoni P; Soffietti R
J Neurooncol; 2019 Oct; 145(1):115-123. PubMed ID: 31556015
[TBL] [Abstract][Full Text] [Related]
7. [Medical Treatments for Malignant Brain Tumor].
Kitamura Y; Toda M
Brain Nerve; 2023 May; 75(5):561-566. PubMed ID: 37194532
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide synthase inhibitors as potential therapeutic agents for gliomas: A systematic review.
Merenzon MA; Hincapie Arias E; Bhatia S; Shah AH; Higgins DMO; Villaverde M; Belgorosky D; Eijan AM
Nitric Oxide; 2023 Sep; 138-139():10-16. PubMed ID: 37279819
[TBL] [Abstract][Full Text] [Related]
9. Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
van den Bent MJ
Semin Oncol; 2003 Dec; 30(6 Suppl 19):39-44. PubMed ID: 14765384
[TBL] [Abstract][Full Text] [Related]
10. [The Role of Chemotherapy in the Treatment of Low-grade Gliomas].
Lakomý R; Kazda T; Poprach A; Pospíšil P; Jančálek R; Šlampa P
Klin Onkol; 2017; 30(5):343-348. PubMed ID: 29031036
[TBL] [Abstract][Full Text] [Related]
11. Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Yao H; Liu J; Zhang C; Shao Y; Li X; Feng M; Wang X; Gan W; Zhou Y; Huang Y
J Clin Neurosci; 2021 Aug; 90():82-88. PubMed ID: 34275586
[TBL] [Abstract][Full Text] [Related]
12. Current concepts and newer developments in the treatment of malignant gliomas.
Omay SB; Vogelbaum MA
Indian J Cancer; 2009; 46(2):88-95. PubMed ID: 19346642
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
14. Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
López-Valero I; Torres S; Salazar-Roa M; García-Taboada E; Hernández-Tiedra S; Guzmán M; Sepúlveda JM; Velasco G; Lorente M
Biochem Pharmacol; 2018 Nov; 157():275-284. PubMed ID: 30125556
[TBL] [Abstract][Full Text] [Related]
15. Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide.
Pinto F; Costa ÂM; Andrade RP; Reis RM
Neurotherapeutics; 2020 Oct; 17(4):2015-2027. PubMed ID: 32785847
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutics in adult malignant brain gliomas.
Reni M; Mazza E; Tosoni A; Brandes AA
Expert Opin Investig Drugs; 2005 Jun; 14(6):643-58. PubMed ID: 16004593
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutic options for primary brain tumors.
Kim L; Glantz M
Curr Treat Options Oncol; 2006 Nov; 7(6):467-78. PubMed ID: 17032559
[TBL] [Abstract][Full Text] [Related]
18. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
20. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
Sun X; Turcan S
Cells; 2021 May; 10(5):. PubMed ID: 34067729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
